- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.10. | Lila Sciences' swollen first round, and other biofinancings | ||
| 17.10. | Merck KGaA joins the Trump MFN gang with IVF deal | ||
| 17.10. | FDA hands out first national priority vouchers to nine firms | ||
| 16.10. | UK starts 'largest-ever' trial of possible Parkinson's drugs | ||
| 16.10. | Merck KGaA looking to rare disease deals to build health momentum | ||
| 16.10. | J&J faces fresh litigation in UK over talc cancer risks | ||
| 16.10. | Bavarian Nordic urges investors to accept takeover offer | ||
| 15.10. | Novo builds pipeline again with $2.1bn Omeros deal | ||
| 15.10. | UK's VR-powered medicine maker scheme delivers first results | ||
| 15.10. | Lilly says oral GLP-1 could be 'foundational' diabetes drug | ||
| 15.10. | Germany's Tubulis raises €308m for ADC pipeline | ||
| 15.10. | J&J streamlines with plan to hive off orthopaedics unit | ||
| 15.10. | Can new Tukysa data drop unlock its sales potential? | ||
| 14.10. | $600m round will help Kailera push obesity drug into phase 3 | ||
| 14.10. | Investor seeks sale of Novavax after poor COVID jab sales | ||
| 14.10. | FDA clears Roche, Lilly Alzheimer's blood test | ||
| 14.10. | Boehringer, Click DTx for schizophrenia clears pivotal trial | ||
| 14.10. | Astellas suffers pancreatic cancer failure with Vyloy | ||
| 13.10. | WHO sounds alarm over rising tide of antibiotic resistance | ||
| 13.10. | UCB drug for rare disease TK2d boosts survival | ||
| 13.10. | Data shows survival gain with UCB drug for rare disease TK2d | ||
| 13.10. | Kelun gets world-first approval for TROP2 ADC | ||
| 13.10. | Chaos as layoffs start to hit HHS agencies | ||
| 13.10. | AstraZeneca joins Pfizer in MFN pricing deal with US | ||
| 10.10. | BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .